Gilead Sciences, Inc. (GIS.F)
| Previous Close | 59.80 |
| Open | 60.72 |
| Bid | 60.55 x 50000 |
| Ask | 60.75 x 50000 |
| Day's Range | 60.72 - 60.72 |
| 52 Week Range | 59.85 - 80.08 |
| Volume | |
| Avg. Volume | 513 |
| Market Cap | 77.152B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 184.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.88 (4.81%) |
| Ex-Dividend Date | Jun 14, 2024 |
| 1y Target Est | N/A |
- ACCESSWIRE
Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead Sciences Forbes has listed Gilead as one of America's Best Employers for Diversity. We believe that by championing inclusion and diversity, we not only enrich our workplace but also drive groundbreaking ...
- Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
- Business Wire
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
